Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Botox-Like shot may give voice disorder patients months of relief

NCT ID NCT05158166

Symptom relief Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new type of botulinum toxin injection (DAXI) for people with adductor spasmodic dysphonia, a condition that causes the voice to spasm and sound strained. 22 adults who had previously been helped by standard Botox injections received a single DAXI injection into their voice box muscles. The goal was to see if DAXI could provide longer-lasting voice improvement, potentially reducing the need for repeat injections every few months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

22 people

The number who actually took part.

Started

Oct 2023

Finished

Mar 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * greater than 18 * diagnosis of adductor spasmodic dysphonia * previous successful treatment with BotoxA * stabilized dose for last 3 treatments Exclusion Criteria: * age less than 18 * exclusively having other neurologic conditions such as: * abductor spasmodic dysphonia * ALS * Multiple sclerosis * Parkinson's disease * Essential tremor

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adductor spasmodic dysphonia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

spasmodic dystonia voice disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adductor spasmodic dysphonia Spasmodic dysphonia Voice disorders

Contacts and locations

Locations

  • UCSF

    San Francisco, California, 94118, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.